SBFM Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

11.20M

+20.39%

11.10M

+31.59%

10.00M

+4.22%

Estimates Revision

The market is revising Downward the revenue expectations for Sunshine Biopharma, Inc. (SBFM) for FY2025, with the revenue forecasts being adjusted by -8.89% over the past three months. During the same period, the stock price has changed by -9.46%.

Revenue Estimates for FY2025

Revise Downward

-8.89%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+21.69%

In Past 3 Month

Stock Price

Go Down

-9.46%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Sunshine Biopharma Inc (SBFM.O) is -2.86, compared to its 5-year average forward P/E of -1.57. For a more detailed relative valuation and DCF analysis to assess Sunshine Biopharma Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.57

Current PE

-2.86

Overvalued PE

0.75

Undervalued PE

-3.89

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.14

Current PS

0.14

Overvalued PS

0.37

Undervalued PS

-0.09

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 11812.88% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

SBFM News & Events

Events Timeline

No data

News

4.0

10-08Benzinga

Aegis Capital Affirms Buy Rating for Sunshine Biopharma, Keeps $7 Price Target Intact

2.0

04-03TipRanks

3 Penny Stocks to Watch Now, 4/3/25

9.0

04-02Benzinga

Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug

People Also Watch

Frequently Asked Questions

What is Sunshine Biopharma Inc (SBFM) stock price today?

The current price of SBFM is 1.34 USD — it has increased 0 % in the last trading day.

What is Sunshine Biopharma Inc (SBFM)'s business?

Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.

What is the price predicton of SBFM Stock?

Wall Street analysts forecast SBFM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SBFM is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Sunshine Biopharma Inc (SBFM)'s revenue for the last quarter?

Sunshine Biopharma Inc revenue for the last quarter amounts to 9.42M USD, increased 11.64 % YoY.

What is Sunshine Biopharma Inc (SBFM)'s earnings per share (EPS) for the last quarter?

Sunshine Biopharma Inc. EPS for the last quarter amounts to -0.19 USD, decreased -79.79 % YoY.

What changes have occurred in the market's expectations for Sunshine Biopharma Inc (SBFM)'s fundamentals?

How many employees does Sunshine Biopharma Inc (SBFM). have?

Sunshine Biopharma Inc (SBFM) has 52 emplpoyees as of December 15 2025.

What is Sunshine Biopharma Inc (SBFM) market cap?

Today SBFM has the market capitalization of 6.57M USD.